Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation

Coya Therapeutics Inc COYA reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for mild to moderate Alzheimer's Disease.

Last month, Coya reported that COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015)

Clinically, evaluation of cognitive function showed that administration of COYA 301 resulted in a statistically significant improvement in mean MMSE scores during the treatment phase, compared to mean MMSE score at baseline (p=0.015). 

Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the end of treatment with COYA 301, compared to pre-treatment baseline scores, indicating no cognitive decline.

COYA 301 administration resulted in a statistically significant reduction of blood biomarkers and peripheral expression of the proinflammatory cytokines.

The consistent reduction of these cytokines correlated with a lack of cognitive decline in the patients throughout the study. 

Further, the significant reduction of proinflammatory cytokine expression and the lack of clinical decline also correlated with a significant increase of regulatory T cell function following the administration of COYA 301.

Price Action: COYA shares are up 4.61% at $4.54 on the last check Wednesday.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechEquitiesNewsPenny StocksHealth CareMarketsMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!